Clinical Trials Logo
  1. Home
  2. Premenstrual Dysphoric Disorder
  3. NCT00620581

Luteal Phase Administration of Paroxetine for the Treatment of PMDD — PMDD  

Premenstrual Dysphoric Disorder Clinical Trial

Official title:
Luteal Phase Administration of Paroxetine for the Treatment of PMDD: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women

Clinical Trial Summary

The efficacy of SSRI use to relieve the symptoms associated with premenstrual dysphoric disorder has been established. We proposed to test the hypothesis that intermittent treatment with paroxetine administered during the luteal phase of the menstrual cycle only is more effective than placebo in improving symptoms of PMDD. This was a double-blind, placebo-controlled, three-arm parallel group study of patients with PMDD. Menstruating women 18 years of age or older who met criteria for inclusion in the study were randomized to one of three arms: paroxetine 10mg/day during the luteal phase of the menstrual cycle; paroxetine 20mg/day during the luteal phase of the menstrual cycle; placebo daily during the luteal phase of the menstrual cycle. The objective was to evaluate the efficacy and safety of intermittent treatment of paroxetine in women with PMDD.

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00620581
Study type Interventional
Source McMaster University
Contact
Status Completed
Phase Phase 3
View Details
See also
  Status Clinical Trial Phase
Completed NCT03862469 - Premenstrual Hormonal and Affective State Evaluation (PHASE) Project N/A
Active, not recruiting NCT00536198 - Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder N/A
Completed NCT03449979 - Single Session of tACS in a Depressive Episode N/A
Completed NCT00516113 - A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria Phase 4
Recruiting NCT05098574 - Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder Phase 2
Withdrawn NCT04123483 - EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders Phase 4
Completed NCT00518570 - Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD) N/A
Not yet recruiting NCT01217775 - Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder Phase 3
Terminated NCT02362191 - Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD N/A
Completed NCT00678574 - The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder Phase 4
Active, not recruiting NCT05327075 - Premenstrual Dysphoric Disorder:Knowledge,Attitude and Practice Among Egyptian Females
Not yet recruiting NCT02448836 - Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD) N/A
Completed NCT01799733 - Alternative Treatments for Premenstrual Dysphoric Disorder N/A
Completed NCT06227676 - Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25 Phase 2/Phase 3
Active, not recruiting NCT02508103 - Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study Phase 2/Phase 3
Completed NCT00927095 - Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD) Phase 4
Completed NCT00089414 - Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives Phase 2
Not yet recruiting NCT06462391 - Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms N/A
Completed NCT01875718 - A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD) Phase 1/Phase 2
Completed NCT06136104 - The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms N/A